Clinical Trials Logo

Iron Overload clinical trials

View clinical trials related to Iron Overload.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06146608 Recruiting - Iron Overload Clinical Trials

Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption

FeMicrobiome
Start date: January 15, 2023
Phase:
Study type: Observational

The FeMicrobiome study will evaluate gut microbiome features and their relationships with dietary iron absorption in healthy adults. The investigators hypothesize that (1) the gut microbiota can be shaped by the heme and non-heme Fe content of the diet and that (2) this will influence individual variation in dietary Fe absorption.

NCT ID: NCT06137079 Recruiting - Iron Overload Clinical Trials

"Iron Overload and Endocrinological Diseases"

Start date: June 20, 2013
Phase:
Study type: Observational

Patients with hemochromatosis or Thalassemia develop progressive tissue and organs damages secondary to iron overload. Iron overload can result both from transfusional hemosiderosis and excess gastrointestinal iron absorption. Iron deposition in the heart, liver, and multiple endocrine glands results in severe damage to these organs, with variable degrees of endocrine and organ failure. Although patients with iron overload often present endocrine disorders, the pathogenetic mechanisms underlying endocrinopathies are not completely clear. In particular it is not elucidated if the spectrum of endocrinopathies could change with advancing age. All endocrinological comorbidities can develop from a primary damage of the target gland, from pituitary secondary failure or from both. The aim of this study is to investigate the prevalence of endocrinological diseases in adult patients with iron overload due to β-thalassemia or hemochromatosis and their impact on well-being and quality of life. The study design is a prospective cross-sectional clinical study. All subjects enrolled will be evaluated for the endocrine diseases. The study protocol will include data collection from family and patients' history of diseases, physical examination, hormonal assessment for all endocrine axes and instrumental examinations. The results will provide evidence on the prevalence of endocrine diseases in patients with iron overload and will add information to characterize the type and the degree of endocrine deficiencies, and on the pathogenic mechanisms involved, in order to individualize diagnostic and therapeutic approaches.

NCT ID: NCT05355766 Recruiting - Thalassemia Clinical Trials

Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients

Start date: June 2, 2022
Phase: Phase 2
Study type: Interventional

The safety and efficacy of CN128 is studied in thalassaemia with sever liver iron overloaded patients.

NCT ID: NCT05294471 Recruiting - Healthy Clinical Trials

Fully Automated High-Throughput Quantitative MRI of the Liver

Start date: October 16, 2023
Phase:
Study type: Observational

The purpose of this research is to see if a new automated magnetic resonance imaging (MRI) method will be able to improve the images taken of the liver. Participants will have either known or suspected liver disease, known or suspected iron overload syndrome, or be a healthy adult. Participants will be in the research study for one day.

NCT ID: NCT04835285 Recruiting - Iron Overload Clinical Trials

MRI T2* Mapping of Myocardium, Liver, Pancreas and Pituitary Gland

Start date: January 21, 2020
Phase: N/A
Study type: Interventional

All patients were investigated using a 3T MRI and 1,5 T MRI scanners. For myocardium, pancreas and pituitary gland iron overload quantification in children we have used special sequences for T2*-mapping. Miocardium, pancreas and pituitary gland T2* relaxometry maps were calculated automatically by commertial application ReportCARD Functool (GE Healthcare) and integrated Philips T2* maps. Then for selected ROI T2* data acquisition in milisecond [ms] were performed and calculated automatically.

NCT ID: NCT04423237 Recruiting - Iron Overload Clinical Trials

Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT

Start date: September 30, 2020
Phase:
Study type: Observational

Hematopoietic Stem Cell Transplantation (HSCT) is currently a standard procedure for a wide range of blood-oncological diseases and genetic disorders. Recent improvements in transplant technologies, infection prevention and graft-versus-host-disease (GVHD) management procedures have significantly reduced the transplant-related mortality (TRM). However, approximately 50% of pediatric patients may develop liver dysfunction before HSCT and 74% to 85.5% after HSCT, with a TRM related to liver dysfunction reaching 46%. The liver and pancreas complications still remain too high for the difficulties and diagnostic inefficiencies and, consequently, for the lack of targeted and safer therapies. The diagnostic problems can be summarized in 3 major points: a) the histological examination of liver and pancreas parenchyma cannot be routinely performed because of the organ anatomy and the relative risk of the bioptic procedures; b) the lack of specific biomarkers or advanced imaging techniques appropriate for the diagnosis of HSCT complications; c) the multifactorial causes of organ complications, as well as drug toxicities, GVHD, siderosis, ductopenia (considered as an index of hepatic GVHD), the accumulation of potentially toxic substances favored by siderosis and ductopenia. In more than 50% of HSCT patients, siderosis and/or ductopenia may represent common pathological conditions. Furthermore, international guidelines issued by onco-hematology and transplantation scientific societies recommend a chelating treatment with deferasirox in all hematological and oncological patients undergoing an intense transfusion regimen. However, in the presence of siderosis and marked ductopenia, patients receiving deferasirox may experience both severe renal and hematological toxicities and lack of effectiveness of the chelating treatment. Therefore, the principal aim of the present retrospective study will be the evaluation of the transplant-related mortality (TRM) in patients requiring a chelation treatment according to the Italian guidelines in pediatric patients

NCT ID: NCT04291352 Recruiting - Thalassemia Major Clinical Trials

Thalassemic Iron Overload Cardiomyopathy is Ameliorated by Taurine Supplementation

TICATS
Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Hypothesis: Taurine, in combination with standard iron chelation therapy, is more effective than chelation therapy alone in reducing cardiac iron overload, oxidative stress and cardiac damage in β-Thalassemia. Protocol: Sixty subjects with transfusion dependent β-Thalassemia receiving deferasirox iron chelation therapy will be recruited and randomized in a 1:1 ratio to either (1) placebo and continuation of their iron chelation or (2) a combination of iron chelation plus taurine. Transfusion and safety visits will be scheduled monthly with clinical/biochemical assessment visits every three months. The efficacy of taurine combined with standard chelation therapy will be assessed at baseline and 12 months posttreatment by both cardiac T2*MRI, and cardiac function. The recruitment period is projected to be 12 months from initiation.

NCT ID: NCT02474420 Recruiting - Iron Overload Clinical Trials

Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients

CANALI
Start date: June 2015
Phase: N/A
Study type: Interventional

This is a randomized, open label, two arms superiority trial of a representative population of patients with a primary diagnosis of transfusion dependent thalassemia with evidence of moderate cardiac iron overload, defined as an average T2* MRI parameter at the mid inter-ventricular septum between 10 and 20ms.

NCT ID: NCT02066012 Recruiting - Clinical trials for Metabolic Syndrome X

MEPHISTO (Macrophage Phenotype In Metabolic Syndrome With Iron Overload)

MEPHISTO
Start date: February 2014
Phase: N/A
Study type: Observational

Dysmetabolic iron overload syndrome (DIOS), is a frequent hepatic iron overload associated with metabolic syndrome. We hypothesize that this mild iron overload can induce a increased macrophagic polarization towards inflammatory types, thereby contributing to cardiovascular risk. Our main objective is to highlight the influence of iron overload on polarization capacity of monocytes into alternative macrophages (called M2). We therefore compare phenotypic markers of monocytes/macrophages between subjects with DIOS, metabolic syndrome without iron overload and lean subjects.

NCT ID: NCT01169961 Recruiting - Iron Overload Clinical Trials

Assessment of Iron Deposition in Major Organs of Hemodialysis Patients

Start date: February 2010
Phase: N/A
Study type: Observational

The purpose of the present study is to evaluate in hemodialysis patients, who have elevated serum ferritin ( >2000ng/ml) and transferrin saturation (TSAT) >30%, iron deposition in the heart, pancreas, liver and spleen using the T2* MRI technique. In addition, we will also measure the free iron forms in the plasma and LPI, LCI in red blood cells, platelets and PMN, in addition to serum hepcidin, TSAT, serum ferritin, CRP and oxidative stress parameters (ROS,GSH, and malonyldialdehyde (MDA).